-
Tropisetron Hydrochloride: Assay Design Guide
2026-09-26
A practical guide to using Tropisetron Hydrochloride (SKU B2258) in receptor-signaling and transporter experiments without mistaking pharmacological effects for assay artifacts. It covers concentration planning, solubility, storage, interpretation, and evidence-based product selection for biomedical laboratories.
-
Metoprolol Tartrate for Selective β1-Blockade
2026-09-25
Use Metoprolol Tartrate to probe cardiac β1 signaling in cardiovascular assays, with practical guidance for compound preparation, controls, and response monitoring. A transplantation study also shows why β-blocker selectivity and model context matter when interpreting effects beyond the heart.
-
Latrunculin A for Actin Dynamics and Viral Assays
2026-09-25
Use Latrunculin A to perturb actin assembly rapidly and reversibly, then connect cytoskeletal changes to cell shape, motility, or infection readouts. A recent duck enteritis virus study provides a practical rationale for pairing actin disruption with targeted tests of the actin–myosin II network—while underscoring the need to separate direct effects from cell-health confounders.
-
nor-NOHA Acetate: Practical Research Workflows
2026-09-24
A hands-on guide to using nor-NOHA acetate to probe arginase activity, HepG2 phenotypes, and vascular function—with practical controls for compound handling and assay interpretation. It also explains how to explore arginine metabolism alongside CD36-driven AML immunosuppression without implying that the pathways are already proven to interact.
-
Acetylcholine Chloride for Gut–Brain Assays
2026-09-24
Use Acetylcholine Chloride as a defined cholinergic stimulus to test receptor-level responses alongside microbiota-driven gut–vagus–brain effects. This workflow translates recent Bacteroides fragilis findings into practical assay controls, fresh-solution handling, and troubleshooting strategies without treating an exogenous stimulus as a substitute for endogenous signaling.
-
NSP15 Screening Highlights Thymopentin and Oleuropein
2026-09-23
A 2021 structure-based screening study prioritized thymopentin and oleuropein as candidate binders of the SARS-CoV-2 RNA-processing enzyme NSP15, with molecular dynamics simulations supporting the stability of the modeled complexes. The results offer a computational starting point for experimental inhibitor testing, not evidence that either compound has demonstrated antiviral efficacy.
-
Naloxone Hydrochloride as a Causal Probe
2026-09-23
Explore how Naloxone hydrochloride can dissect opioid receptor signaling in withdrawal, anxiety, neural stem cell, and immune assays. This evidence-led guide connects the CCK-8 morphine-withdrawal study to more rigorous opioid addiction and withdrawal studies.
-
PRDX5 Acetylation in Retinal I/R Injury
2026-09-22
The reference study identifies PRDX5 acetylation as a functional modifier of retinal ischemia–reperfusion injury, linking this post-translational change to oxidative stress, mitochondrial dysfunction, and neuronal apoptosis. By combining an acute high intraocular pressure mouse model with OGD/R-treated R28 cells, the work suggests that preserving PRDX5 activity may be more informative than measuring PRDX5 abundance alone.
-
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-09-22
A practical guide to applying hypersensitive ECL chemistry when conventional immunoblots cannot reliably resolve low-abundance targets. The workflow connects HRP-based detection with autophagy and lysosomal biology, while emphasizing controls, quantitative imaging, and troubleshooting.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-21
The FITC Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescein-conjugated secondary antibody for detecting rabbit primary antibodies in immunofluorescence, flow cytometry, and fluorescence microscopy. Its affinity-purified polyclonal design supports signal amplification, while defined storage conditions help preserve reagent performance.
-
α-Eudesmol Protects Against Focal Ischemic Brain Injury
2026-09-21
The reference study connected inhibition of ω-agatoxin IVA-sensitive presynaptic calcium channels with reduced glutamate overflow and protection from focal ischemic brain injury in rats. Its combined synaptosome, microdialysis, and middle cerebral artery occlusion design provides a useful mechanistic framework for interpreting Cav2.1-linked neuroprotection while also showing why channel selectivity must be tested carefully.
-
o-Agatoxin IVA and Cortical Excitotoxicity
2026-09-20
Lustig, Ahern, and Greenberg tested whether the P/Q-type calcium channel antagonist ω-agatoxin IVA could protect cortical neurons from excitotoxic injury triggered by veratridine, ouabain, or NMDA. The study found no reduction in LDH-defined toxicity, showing that inhibition of presynaptic glutamate release does not necessarily prevent downstream neuronal death.
-
o-Agatoxin IVA and Excitotoxicity in Cortical Neurons
2026-09-19
This study tested whether blocking P- and Q-type voltage-gated calcium channels with o-Agatoxin IVA could protect cultured cortical neurons from excitotoxic injury. Its central finding was negative but informative: inhibition of glutamate release or selected calcium-channel subtypes did not prevent toxicity caused by veratridine, ouabain, or NMDA, cautioning against equating reduced transmitter release with neuroprotection.
-
Acetylcholine Chloride in Cell Assays
2026-09-18
Learn how Acetylcholine Chloride, SKU B1596, can improve the control and interpretation of cholinergic stimulation in cell viability, proliferation, cytotoxicity, and gut–brain experiments. This scenario-based guide connects reagent handling, assay design, receptor biology, and recent gut-brain evidence without overstating what a cell assay can demonstrate.
-
Lithium, Exosomal Wnt10a, and Bone Regeneration
2026-09-18
This study identifies a mechanistic route by which lithium enhances BMSC osteogenesis: MARK2-associated Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a release and activates Wnt/β-catenin signaling. Lithium-conditioned exosomes and GelMA-based delivery improved osteogenic outcomes, providing a framework for cell-free bone-regeneration strategies while highlighting the need for careful pathway-specific validation.